Insider Selling: Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $32,686.95 in Stock

Posted by Stanley Muller on Aug 29th, 2026

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) insider Peter Kaiser sold 3,035 shares of the company’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $10.77, for a total value of $32,686.95. Following the transaction, the insider directly owned 264,378 shares of the company’s stock, valued at approximately $2,847,351.06. The trade was a 1.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ocular Therapeutix Trading Down 4.3%

Shares of NASDAQ:OCUL opened at $10.36 on Friday. The business’s 50 day moving average price is $9.68 and its 200-day moving average price is $9.17. Ocular Therapeutix, Inc. has a 1 year low of $6.23 and a 1 year high of $16.44. The firm has a market capitalization of $2.28 billion, a price-to-earnings ratio of -7.30 and a beta of 0.93. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.10 and a quick ratio of 13.03.

Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.05. The company had revenue of $13.47 million during the quarter, compared to analyst estimates of $13.20 million. Ocular Therapeutix had a negative net margin of 579.10% and a negative return on equity of 59.89%. The firm’s revenue was down .1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.39) EPS. On average, equities research analysts forecast that Ocular Therapeutix, Inc. will post -1.47 earnings per share for the current fiscal year.

Institutional Trading of Ocular Therapeutix

Large investors have recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC raised its holdings in shares of Ocular Therapeutix by 124.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,242 shares during the period. Rockefeller Capital Management L.P. acquired a new stake in Ocular Therapeutix during the fourth quarter worth about $31,000. Hilton Head Capital Partners LLC raised its stake in Ocular Therapeutix by 30.4% during the first quarter. Hilton Head Capital Partners LLC now owns 4,520 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 1,053 shares during the period. Atlas Capital Advisors Inc. purchased a new position in Ocular Therapeutix during the fourth quarter worth about $61,000. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in Ocular Therapeutix by 420.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 6,412 shares of the biopharmaceutical company’s stock valued at $78,000 after purchasing an additional 5,179 shares during the last quarter. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Friday, July 17th. Wall Street Zen raised Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Robert W. Baird increased their price objective on Ocular Therapeutix from $24.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. Needham & Company LLC restated a “buy” rating and issued a $18.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, May 5th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $30.00 target price on shares of Ocular Therapeutix in a report on Wednesday, May 6th. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $25.75.

Check Out Our Latest Report on Ocular Therapeutix

Ocular Therapeutix Company Profile

(Get Free Report)

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.